Meningococcal vaccine is the name for any shot that protects against getting sick from Neisseria meningitidis. The effectivity of the vaccine is between 85% and 100% for at least two years. Meningitis and sepsis are less likely to happen in places where they are used a lot. They can be injected into a muscle or given just under the skin. A substantial number of travelers to sub-Saharan Africa is anticipated to drive the global meningococcal vaccines market during the forecast period. In addition, the suggestion of various regulatory bodies for meningococcal vaccination is anticipated to boost market growth. Travelers pose uncertain risks, making vaccine recommendations challenging. This circumstance may slow market growth. Also, meningococcal immunization is voluntary in some countries, limiting market expansion.
Globally, The Meningococcal Vaccines Market of meningococcal vaccines is estimated to reach at a CAGR of 12.7% from 2020 to 2027.
Key Manufacturers in the Meningococcal Vaccines Industry:
1. Baxter International, Inc.
Baxter International, Inc. is an American multinational healthcare company, founded in 1931 and headquartered in Illinois, United States. It operates in in more than 100 countries including the United States, Canada, Mexico, Europe, Australia, Asia, Latin America, and the Middle East. In May 2023, Baxter Signs a Final Agreement to Sell its BioPharma Solutions Business to Advent International and Warburg Pincus.
2. Biomed Pvt. Ltd.
Biomed Pvt. Ltd. is a manufacturer of infusion therapy, iv catheter - infusion therapy & respiratory devices, founded in 1972 and headquartered in National Capital Region of India, India. It operates in 68 countries. Bio-Med vaccines have not only become the first choice of doctors all over the Indian subcontinent, but they have also made a big impression on the international market.
3. GlaxoSmithKline plc GlaxoSmithKline plc (an acronym from its former name GlaxoSmithKline plc,) is a British multinational pharmaceutical and biotechnology company, founded in 2000 with global headquarters in London, England. It operates in 160 national markets. In March 2023, GSK plc will get good results from the MenABCWY combination vaccine candidate's most important phase 3 clinical study. People between the ages of 10 and 25 will get two shots of the vaccine.
4. JN-International Medical Corporation
JN-International Medical Corporation is a U.S.-based biopharmaceutical corporation focused on developing vaccines and diagnostics for infectious disease for developing countries, founded in 1998 and headquartered in Omaha, Nebraska. It operates in more than 30 countries. As of May 27, 2023, the company, formerly called Jeeri Neotech International, Inc., makes vaccines and tests for infectious diseases in poor countries. The company has made a vaccine for Meningococcal meningitis serogroups A, C, Y, and W-135. Herpes and Hepatitis C medicines are also being made by the company.
5. Novartis International AG.
Novartis International AG. is a Swiss multinational pharmaceutical corporation founded in 1996 and is headquartered in Basel, Switzerland. It operates in 140 countries.
6. Pfizer, Inc.
Pfizer, Inc. is an American multinational pharmaceutical and biotechnology corporation founded in 1849 and headquartered in New York City, United States. It operates in 181 countries. In December 2022, Pfizer Inc. stated that the U.S. Food and Drug Administration (FDA) had accepted for study a Biologics License Application (BLA) for its investigational pentavalent meningococcal vaccine candidate (MenABCWY). Pfizer sent in MenABCWY to protect people between the ages of 10 and 25 from meningococcal disease caused by the most common serogroups.
7. Sanofi SA
Sanofi SA is a French multinational pharmaceutical and healthcare company, founded in 1973 and headquartered in Paris, France. It operates in more than 70 countries worldwide. In April 2020, the U.S. FDA gave Sanofi permission to sell MenQuadfi. It is a meningococcal (Groups A, C, Y, and W) conjugate vaccine to protect adults 2 years and older from getting invasive meningococcal disease.
8. Serum Institute of India Ltd.
Serum Institute of India Ltd. has made and sold more than 1.5 billion doses of vaccines around the world. These vaccines include Polio vaccine, Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps, Rubella, Pneumococcal, and Covid-19 vaccines, founded in 1966 and headquartered in Maharashtra, India. It operates in around 170 countries globally. A study conducted in May 2023 revealed, that the novel meningococcal vaccination from the Serum Institute of India could eliminate meningitis in Africa. Immune response and safety were good with the vaccination. NmCV-5 produced a robust immune response across five meningococcal strains in 1,800 healthy Mali and Gambia residents aged 2–29 in 2021. GSK's quadrivalent meningococcal vaccination MenACWY-D produced a weaker response.
*Definition: Neisseria meningitidis, often known as meningococcus, is a Gram-negative bacterium that can cause meningitis and other meningococcal disorders including meningococcemia. Meningococcal vaccination is used to prevent diseases caused by this bacterium.
